

General information about company

Scrip code*	540679	
NSE Symbol*	HALEOSLABS	
MSEI Symbol*	NOTLISTED	
ISIN*	INE320X01016	
Name of company	Haleos Labs Limited	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	11-02-2026	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-02-2026	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Third quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Unaudited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited	
Segment Reporting	Single segment	
Description of single segment	Bulk Drugs / API's	
Start date and time of board meeting	11-02-2026 16:45	
End date and time of board meeting	11-02-2026 18:50	
Whether cash flow statement is applicable on company		
Type of cash flow statement		
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No	
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	No default

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-12-2025	31-12-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	8071.91	23760.54
	Other income	7.84	147.05
	Total income	8079.75	23907.59
2	Expenses		
(a)	Cost of materials consumed	3935.67	11459.55
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-21.45	82.81
(d)	Employee benefit expense	1246.18	3733.2
(e)	Finance costs	145.96	469.74
(f)	Depreciation, depletion and amortisation expense	269.09	800.84
(g)	Other Expenses		
1	Manufacturing Expenses	1495.52	4357.51
2	Other Expenses	260.01	802.6
	Total other expenses	1755.53	5160.11
	Total expenses	7330.98	21706.25
3	Total profit before exceptional items and tax	748.77	2201.34
4	Exceptional items	0	0
5	Total profit before tax	748.77	2201.34
6	Tax expense		
7	Current tax	200	625
8	Deferred tax	8.09	22.13
9	Total tax expenses	208.09	647.13
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	540.68	1554.21
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	540.68	1554.21
17	Other comprehensive income net of taxes	0.91	2.61
18	Total Comprehensive Income for the period	541.59	1556.82
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		

	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	302.33	302.33	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	17.88	51.41	
	Diluted earnings (loss) per share from continuing operations	17.88	51.41	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	17.88	51.41	
	Diluted earnings (loss) per share from continuing and discontinued operations	17.88	51.41	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Other Comprehensive Income

	Date of start of reporting period	01-10-2025	01-04-2025
	Date of end of reporting period	31-12-2025	31-12-2025
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	-1.28	-3.68
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.37	1.07
5	Total Other comprehensive income	0.91	2.61

General information about company

Scrip code*	540679
NSE Symbol*	HALEOSLABS
MSEI Symbol*	NOTLISTED
ISIN*	INE320X01016
Name of company	Haleos Labs Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	11-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-02-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Third quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	Bulk Drugs / API's
Start date and time of board meeting	11-02-2026 16:45
End date and time of board meeting	11-02-2026 18:50
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-12-2025	31-12-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	9478.31	25865.54
	Other income	18.34	150.38
	Total income	9496.65	26015.92
2	Expenses		
(a)	Cost of materials consumed	4473.9	11298.55
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-111.86	-320.68
(d)	Employee benefit expense	1669.65	4921.66
(e)	Finance costs	154.43	502.48
(f)	Depreciation, depletion and amortisation expense	390.99	1162
(g)	Other Expenses		
1	Manufacturing Expenses	1752.02	5134.56
2	Other Expenses	289.75	888.27
	Total other expenses	2041.77	6022.83
	Total expenses	8618.88	23586.84
3	Total profit before exceptional items and tax	877.77	2429.08
4	Exceptional items	0	0
5	Total profit before tax	877.77	2429.08
6	Tax expense		
7	Current tax	200	625
8	Deferred tax	12.88	58.45
9	Total tax expenses	212.88	683.45
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	664.89	1745.63
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	664.89	1745.63
17	Other comprehensive income net of taxes	4.27	11.79
18	Total Comprehensive Income for the period	669.16	1757.42
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent	661.68	1687.63
	Total profit or loss, attributable to non-controlling interests	3.21	58
20	Total Comprehensive income for the period attributable to		

	Comprehensive income for the period attributable to owners of parent	664.61	1695.75	
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	4.55	61.67	
21	Details of equity share capital			
	Paid-up equity share capital	302.33	302.33	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	21.89	55.82	
	Diluted earnings (loss) per share from continuing operations	21.89	55.82	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	21.89	55.82	
	Diluted earnings (loss) per share from continuing and discontinued operations	21.89	55.82	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Other Comprehensive Income

	Date of start of reporting period	01-10-2025	01-04-2025
	Date of end of reporting period	31-12-2025	31-12-2025
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	-5.82	-16.08
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	1.55	4.29
5	Total Other comprehensive income	4.27	11.79